FindTrial
Sign In

A Multicenter Randomized Controlled Study About the Intervention Timing of Thoracic Endovascular Aortic Repair in Acute Uncomplicated Type B Aortic Dissection Patients

A Multicenter Randomized Controlled Study About the Intervention Timing of Thoracic Endovascular Aortic Repair in Acute Uncomplicated Type B Aortic Dissection Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000029473
Enrollment
Unknown
Registered
2020-02-02
Start date
2020-03-01
Completion date
Unknown
Last updated
2020-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aortic dissection

Interventions

Acute group:treated with thoracic endovascular aortic repair within 14 days from the onset of symptoms to admission
Sub-acute group:treated with thoracic endovascular aortic repair within 15 to 28 days from the onset of symptoms to admission

Sponsors

Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Diagnosed with uncomplicated type B aortic dissection; 2. Within 14 days from the onset of symptoms to admission; 3. Agree and fit for thoracic endovascular aortic repair; 4. The patient understood the situation and signed the informed consent voluntarily.

Exclusion criteria

Exclusion criteria: 1. The ascending aorta involved; 2. Impending rupture or aortic rupture; 3. Limb or organ ischemia; 4. Mental disorder or alcohol dependence; 5. Not suitable for thoracic endovascular aortic repair; 6. Heritable aortic diseases, including Turner syndrome, Marfan syndrome, Ehlers-Danlos syndrome, Loeys-Dietz sundrome and so on; 7. Rheumatic immune diseases, including Takayasu arteritis, giant cell arteritis, polyarteritis nodosa and so on; 8. Trauma-induced acute uncomplicated type B aortic dissection; 9. Iatrogenic acute uncomplicated type B aortic dissection; 10. Pregnancy; 11. The expected survival time is less than 1 year; 12. Previous aortic surgery history; 13. Participants in other clinical trials.

Design outcomes

Primary

MeasureTime frame
All-cause mortality;major adverse cardiovascular events (MACE);All-cause mortality;major adverse cardiovascular events (MACE);—

Secondary

MeasureTime frame
Total hospitalization costs;Total length of stay;—

Countries

China

Contacts

Public ContactJianfang Luo

Guangdong Provincial People's Hospital

jianfangluo@sina.com+86 13602833227

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026